 BOSTON and ROCKVILLE, Md., Feb. 10, 2021 GLOBE NEWSWIRE -- Sensei Biotherapeutics, Inc., a clinical-stage immunotherapy company focused on the discovery and development of next generation therapeutics for cancer, today announced the closing of its initial public offering of 7,000,052 shares of its common stock on February 8, 2021, as well as the issuance of an additional 1,030,243 shares pursuant to the exercise by the underwriters of their option to purchase additional shares on February 10, 2021, at a public offering price of 19.00 per share. The gross proceeds to Sensei from the two closings, before deducting underwriting discounts and commissions and other offering expenses payable by Sensei, were approximately 152.6 million. All of the shares in the offering were offered by Sensei. Senseis common stock is listed on the Nasdaq Global Market under the ticker symbol SNSE. 